Key result
Age over 50 linked to ~28-point higher bleeding rate on higher-dose warfarin.
Why the study?
Warfarin is widely used but associated with bleeding complications due to its narrow therapeutic index, and factors influencing warfarin toxicity in Indian patients need determination.
Cross-Sectional (n=80)
No
May warrant closer bleeding surveillance in older patients on higher-dose warfarin; leaves open need for prospective dose-adjustment trials.
Background: Warfarin is widely used anticoagulant in treatment and prevention of thrombosis. Despite its common use, warfarin can be associated with bleeding complications because of its narrow therapeutic index. A review of many studies show average yearly rates of warfarin related bleeding as high as 0.5% , 4.9% , 15% for fatal, major, minor bleeding complications. The study is to determine age, gender, pharmacogenetics, drugs influencing warfarin toxicity in Indian patients.Methods: Observational and cross-sectional study was conducted over period of 1 year after obtaining institutional ethics committee permission. Written and informed consent was taken from patients admitted in tertiary care hospital who fulfilled inclusion and exclusion criteria.Results: Most common age for Warfarin toxicity in our study was between 30 to 39 years (22.5%) with mean of 42.9 years. Bleeding risk was higher in elderly with 14 out of 26 patients with age >50 years had bleeding manifestations. Toxicity was more prevalent in female (60%). 40% patients were on drugs interacting with warfarin; NSAIDS (Nonsteroidal Anti-Inflammatary Drug) and antibiotics were the most common interacting drugs. In our study, 17.5% patients had acute liver disease and one patient had deranged creatinine (2.6). 40% of patients had VKORC1 variants and 35% of patients had CYP2C9 variants. Maximum patients developed toxicity within 15-30 days of initiation of warfarin.Conclusions: Warfarin toxicity has multifactorial cause. Drugs and Genetic variation are most common factors influencing warfarin toxicity. Warfarin toxicity has low mortality rate, although it increases with (International Normalised Ratio) INR>10 and with increasing age.
No takes yet. Share an insight, caveat, or question.
Salagre et al. (2017) conducted a cross-sectional in Warfarin toxicity (n=80). Age >50 years and warfarin dose ≥5 mg/day vs. Age <50 years and warfarin dose ≥5 mg/day was evaluated on Bleeding manifestations (p=0.033). Older age (>50 years) was significantly associated with a higher rate of bleeding manifestations compared to younger patients when receiving warfarin doses of ≥5 mg/day (60.0% vs 31.8%, p=0.033).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: